Send Message
Home > products > Anti-Tumor > Ixazomib Citrate (1201902-80-8)

Ixazomib Citrate (1201902-80-8)

Product:
Ixazomib
Description:
CAS: 1201902-80-8; Ixazomib manufacturer; Ixazomib API; Ixazomib proteasome inhibitor; Anti-Tumor
Category:
Anti-Tumor
In-stock:
In Stock
Payment Method:
L/C, T/T
Shipping Method:
AIR, Express
Specifications
CAS:
1201902-80-8
Specification:
CP, EP, In-house, As Required
M.F.:
C20H23BCl2N2O9
M.W.:
517.12
Assay:
98%
Shelf Life:
2 Years
Package:
25kg/drum
High Light:

Ixazomib Citrate 1201902-80-8

,

Ixazomib API 1201902-80-8

,

Ixazomib proteasome inhibitor

Introduction

Ixazomib Citrate (1201902-80-8)

 

Ixazomib citrate is a proteasome inhibitor that acts by preventing cell growth in solid tumours. It is an anti-cancer agent that is used for treatment of multiple myeloma. Compared with bortezomib, Ixazomib citrate obtains higher pharmacokinetics, efficacy, and anticancer activity.

 

Ixazomib Citrate (1201902-80-8) 0

 

Product Name: Ixazomib Citrate
CAS No.: 1201902-80-8
Assay: 98%
Specification: CP, EP, In-house, as required
Molecular Formula: C20H23BCl2N2O9
Molecular Weight: 517.12
Shelf Life: 2 Years
Package: 25kg/drum

 

Ixazomib Citrate (1201902-80-8) 1

Ixazomib Citrate (1201902-80-8) 2

Ixazomib Citrate (1201902-80-8) 3

Send RFQ
Stock:
In Stock
MOQ: